Product Description
Bonstosis SN Tablets contain Withania Somnifera 250 mg + N-acetylglucosamine 200 mg + Silymarin Extract 150 mg + Boswellia Serrata Extract 125 mg + Zngiber Officinale Extract 24 mg + Curcuma Longa Extract 18 mg. They combine glucosamine, a joint-support formulation, with silymarin, a liver-protective (silymarin). Available from Pharmakon Lifesciences, Karnal, for PCD franchise and third-party manufacturing.
Indications
Osteoarthritis and joint pain
Cartilage and joint health
Liver support in fatty liver and liver injury
Loss of appetite
Dosage
As directed by the physician or dietitian. Do not exceed the recommended dose.
Side Effects
Generally well tolerated; mild stomach upset may occur. Do not exceed the recommended dose.
Storage Instructions
Store in a cool, dry place below 30°C, protected from light and moisture.
Keep out of the reach of children.
Availability
Bonstosis SN Tablets is available for PCD Pharma Franchise distribution and Third-Party Contract Manufacturing across India. Reach out to the manufacturer for pricing, MOQ and territory details.
Pharmaceutical Specifications
| Product Name | Bonstosis SN Tablets |
| Dosage Form | Tablet |
| Composition | Withania Somnifera 250 mg + N-acetylglucosamine 200 mg + Silymarin Extract 150 mg + Boswellia Serrata Extract 125 mg + Zngiber Officinale Extract 24 mg + Curcuma Longa Extract 18 mg |
| Strength | N/A |
| Packing | 10x1x10 Alu-Alu (Mono Carton) |
| MRP | On Request |
| Prescription | OTC (Non-Schedule) |
| Manufactured by | Pharmakon Lifesciences, Karnal |
| Delivery Time | 15–25 working days |
| Certifications | ISO 9001:2015 · WHO-GMP · Verified Company |
Company Information
Pharmakon Lifesciences
Karnal-based pharma company offering PCD franchise and third-party manufacturing in neuro, derma, gynae, ortho, dental and paediatric ranges. Operating since 2018.